ARAC-8C cell line

Case ID:
Web Published:

Technology Overview:

Two nucleoside transport-deficient cell lines were developed through isolation from a hypoxanthine-guanine phosphoribosyltransferase-deficient derivative of wild type CEM cells (a human T lymphoblast cell line originally derived from a patient with acute lymphocytic leukemia).  The Ara-C/8C and TUB-4D clones were isolated by virtue of their resistance to 8 µM arabinosylcytosine and 4µM tubercidin, respectively.  One cell line completely deficient in deoxycytidine kinase activity, the Ara-C/8D clone, is a clonal derivative of an hypoxanthine-guanine phosphoribosyltransferase-deficient parent CEM cell line originally isolated in semi-solid agarose containing 8µM arabinosylcytosine.  The Ara-C/8C and TUB-4D cell lines are cross-resistant to a spectrum of cytotoxic nucleosides to which parental and Ara-C/8D cell are sensitive. 

Cytarabine (Ara-C), a pyrimidine analog, is a conventional anti-cancer chemotherapeutic commonly used for the treatment of acute myeloid leukemia.  Although Ara-C treatment often induces partial or complete remission of cancerous tissue, many patients eventually develop resistance.  Ara-C/8C cells demonstrate cross-resistance to gemcitabine and 2’, 3’-dideoxycytidine.  Therefore, this cell line may be useful for research into nucleoside transport deficiencies as well as anti-cancer chemotherapeutic analysis.

Links/Publications:  Ulllman et al., J Biol Chem. 1988 Sep 5;263(25):12391-6. 

Licensing Opportunity:  The cell lines are available for non-exclusive licensing.


Patent Information:
Biological Materials
For Information, Contact:
Trina Voss
Technology Development Manager
Oregon Health & Science University
Buddy Ullman
Biological Materials
Biological Materials - Cell Lines
© 2023. All Rights Reserved. Powered by Inteum